Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Richmond Hosts CPR Training for Restart a Heart Day

16
October 2024

Richmond took part in Restart a Heart Day today (Wednesday 16th October

View article

Richmond CEO Presents Landmark Data on Repeat-Dose Gene Editing

9
September 2024

Richmond CEO Presents Landmark Data on Repeat-Dose Gene Editing

View article

Richmond promotes new Director of Communications and Participant Engagement

12
August 2024

Richmond Pharmacology is delighted to announce the promotion of Liz Romano to the new position of Director of Communications and Participant Engagement.

View article

Richmond Chief Medical Director calls for a ‘toolbox’ of standards and guidelines for clinical trials

5
August 2024

The British Journal of Clinical Pharmacology has published an editorial by Richmond’s Dr Ulrike Lorch and Professor Charles Vincent of Oxford University calling for a ‘toolbox’ of practical standards and guidelines for early phase clinical trials.

View article

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

27
June 2024

Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.

View article

A first of a kind trial in the fight against malaria

12
June 2024

Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.

View article

Latest news

Richmond Hosts CPR Training for Restart a Heart Day

October 16, 2024
Richmond took part in Restart a Heart Day today (Wednesday 16th October
Read more

Richmond CEO Presents Landmark Data on Repeat-Dose Gene Editing

September 9, 2024
Richmond CEO Presents Landmark Data on Repeat-Dose Gene Editing
Read more

Events

Pulse Virtual: Respiratory, CVD, Diabetes and Nutrition

Wednesday 18th September
Richmond will be presenting at the upcoming Pulse Virtual Event aimed at GPs
View event